Literature DB >> 3520826

Active immunotherapy against cancer: present status.

D L Morton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3520826

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

1.  Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  K D Kim; H G Lee; J K Kim; S N Park; I S Choe; Y K Choe; S J Kim; E Lee; J S Lim
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 2.  Tumor vaccines.

Authors:  J C Bystryn
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

3.  Discontinuing therapy in childhood acute lymphoblastic leukemia treated with a chemoimmunotherapy protocol.

Authors:  Y Komada; E Azuma; H Yamamoto; S Tanaka; K Shimizu; H Kamiya; M Sakurai; T Izawa
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Authors:  D L Morton; L J Foshag; D S Hoon; J A Nizze; E Famatiga; L A Wanek; C Chang; D G Davtyan; R K Gupta; R Elashoff
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.